Frisco, Texas, USA, April 18, 2016 – OxySure Therapeutics, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen products with its “oxygen from powder” technology and other innovative emergency medical solutions today provided a corporate update.
The Company announced that it had effected a reverse split of its common stock at a ratio of 1-for-50. The reverse split is subject to the Financial Industry Regulatory Authority (FINRA) declaring it effective. In addition, the Board of Directors made the decision that, in the light of many factors at this time, the cost of continuing the Company’s public filings are outweighing the benefits for the foreseeable future. For that reason, the Company filed a notice of termination to suspend its duty to file reports with the Securities and Exchange Commission.
The Board of Directors thanked all the Company’s stakeholders for their continued support as the Company kept moving forward.
About OxySure Therapeutics, Inc.
OxySure Therapeutics, Inc. (OTCQB: OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products and pulse oximetry products.www.OxySure.com
Statements in this earnings release that are not historical facts are considered to be forward-looking statements. Such statements include, but are not limited to, statements regarding management beliefs and expectations, based upon information available at the time the statements are made, regarding future plans, objectives and performance. All forward-looking statements are subject to risks and uncertainties, many of which are beyond management’s control and actual results and performance may differ significantly from those contained in forward-looking statements. OxySure Therapeutics, Inc. intends any forward-looking statement to be covered by the Litigation Reform Act of 1995 and is including this statement for purposes of said safe harbor provisions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. OxySure Therapeutics, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date as of which such statements are made. A discussion of certain risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements is included in OxySure Therapeutics, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2014.
RB Milestone Group, LLC
+1 (212) 661-0075